Meeting
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
Authors
Filip Janku
The University of Texas MD Anderson Cancer Center, Houston, TX
Filip Janku , Gopa Iyer , Anna Spreafico , Noboru Yamamoto , Yung-Jue Bang , Elena Elez , Maja J. De Jonge , Harry J.M. Groen , Frederik Marmé , Kathrin Gollmer , Annie St-Pierre , Maritza Melendez , Anna Mais , Heidi Nauwelaerts , Uz M. Stammberger , Reinhard Dummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02607813
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2586)
DOI
10.1200/JCO.2018.36.15_suppl.2586
Abstract #
2586
Poster Bd #
412
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
First Author: Kristen Renee Spencer
Poster
2014 Gastrointestinal Cancers Symposium
Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
First Author: Yasuhide Yamada
Poster
2013 ASCO Annual Meeting
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
First Author: Alex A. Adjei